Raph Leonardus Hamers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Raph Leonardus Hamers has a total of 758 co-authors. Here are the top co-authors by number of shared publications:
- Ralalicia Limato
Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
13 shared publications - Guy Edward Thwaites
Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom
12 shared publications - Henry Surendra
Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
11 shared publications - Erni Juwita Nelwan
Division of Tropical Medicine and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
8 shared publications - Hindrik Rogier van Doorn
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
8 shared publications Manzilina Mudia
Faculty of Medicine Oxford University Clinical Research Unit Indonesia, Universitas Indonesia Jakarta Indonesia
8 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Impact of COVID-19 pandemic on childhood immunization coverage in Indonesia: lesson learned from a nationwide analysis of the Expanded Programme on Immunization
Background: The COVID-19 pandemic disrupted childhood immunization programmes in many countries worldwide. However, evidence on its impact in low and middle-income countries remains limited. This study examined the impact of the COVID-19 pandemic on childhood immunization coverage across 514 districts in Indonesia and identified district-level associated factors. Methods: We conducted a nationwide longitudinal analysis of the Expanded Programme on Immunization to compare immunization coverage before and after the pandemic. The outcome variable was the annual childhood immunization coverage (proportion of children aged 0–12 months who have received all recommended doses of childhood immunization as per the national immunization schedule). The independent variables include COVID-19 burden and vaccination rates, health system and human development indicators. Mixed-effect logistic regression was done to assess association between the independent and outcome variables. Results: At the national level, the coverage was 83.2% in pre-pandemic, 75.0% in the first year of pandemic, and 88.6%, in the second. In the first year, 69.3% of districts experienced significant decline, with a lower national coverage ratio of 0.92 (95% confidence interval 0.89–0.94). In the second year, 36.2% districts were still affected. The multivariable analysis showed that a significant decline in coverage during the first pandemic year was associated with high COVID-19 incidence (adjusted odds ratio 2.19, 95%CI 1.01–4.73 for the highest vs. lowest group), low midwife adequacy (5.84, 2.40–14.16 for the lowest vs. the highest group, 2.61, 1.26–5.40 for low-middle vs. the highest group), and a high proportion of health facility-based births (2.98, 1.49–5.98 for middle-high vs. the lowest group). Conclusions: The COVID-19 pandemic was negatively and unevenly associated with childhood immunization in Indonesia, with greatest impacts in districts facing a higher COVID-19 burden and weaker health system capacity. These findings underscore the need for targeted efforts to strengthen the local health system for future health crises.
- 21 July 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Open AccessImpact of COVID-19 pandemic on childhood immunization coverage in Indonesia: lesson learned from a nationwide analysis of the Expanded Programme on Immunization
Background: The COVID-19 pandemic disrupted childhood immunization programmes in many countries worldwide. However, evidence on its impact in low and middle-income countries remains limited. This study examined the impact of the COVID-19 pandemic on childhood immunization coverage across 514 districts in Indonesia and identified district-level associated factors. Methods: We conducted a nationwide longitudinal analysis of the Expanded Programme on Immunization to compare immunization coverage before and after the pandemic. The outcome variable was the annual childhood immunization coverage (proportion of children aged 0–12 months who have received all recommended doses of childhood immunization as per the national immunization schedule). The independent variables include COVID-19 burden and vaccination rates, health system and human development indicators. Mixed-effect logistic regression was done to assess association between the independent and outcome variables. Results: At the national level, the coverage was 83.2% in pre-pandemic, 75.0% in the first year of pandemic, and 88.6%, in the second. In the first year, 69.3% of districts experienced significant decline, with a lower national coverage ratio of 0.92 (95% confidence interval 0.89–0.94). In the second year, 36.2% districts were still affected. The multivariable analysis showed that a significant decline in coverage during the first pandemic year was associated with high COVID-19 incidence (adjusted odds ratio 2.19, 95%CI 1.01–4.73 for the highest vs. lowest group), low midwife adequacy (5.84, 2.40–14.16 for the lowest vs. the highest group, 2.61, 1.26–5.40 for low-middle vs. the highest group), and a high proportion of health facility-based births (2.98, 1.49–5.98 for middle-high vs. the lowest group). Conclusions: The COVID-19 pandemic was negatively and unevenly associated with childhood immunization in Indonesia, with greatest impacts in districts facing a higher COVID-19 burden and weaker health system capacity. These findings underscore the need for targeted efforts to strengthen the local health system for future health crises.
- 3 June 2026
- Published by Elsevier in The Lancet HIV
- Vol. 13 (6) , e363
HIV prevention must incorporate acute HIV infection screening
- 3 June 2026
- Published by Elsevier in The Lancet HIV
- Vol. 13 (6) , e363
HIV prevention must incorporate acute HIV infection screening
- Open Access
- 29 May 2026
- Published by Wiley in Tropical Medicine & International Health
- Vol. 31 (9) , 1231-1237
Aetiology and Antibiotic Susceptibility of Common Bacterial Infections in Hospitalised Patients: A 2019 Multisite Cross‐Sectional Survey in Jakarta, Indonesia
Objectives: To describe the aetiology and antibiotic susceptibility patterns of common bacterial infections in hospitalised patients in Jakarta, Indonesia. Methods: We conducted a hospital‐wide point prevalence survey in six hospitals in 2019, capturing data from routinely ordered bacterial cultures taken before the start of antibiotic treatment. We report relevant bacteria‐antibiotic combinations for Escherichia coli and the ESKAPE group of pathogens. Results: A total of 562 patients (52% women, median age 46 years) were diagnosed with 587 infections, comprising 414 community‐acquired and 173 hospital‐acquired infections, with pneumonia most frequent (258, 44%). From 615 samples collected, 279 (45%) bacterial isolates were identified, of which 213 (76%) gram‐negative, including Klebsiella pneumoniae (68, 24%), Escherichia coli (37, 13%) and Pseudomonas aeruginosa (35, 13%) among others, and 66 (24%) gram‐positive, including Enterococcus faecalis (17, 6%) and Staphylococcus aureus (11, 4%) among others. Proportions of bacteria resistant to third‐generation cephalosporins (3GC) were 75% (47/63) for Klebsiella pneumoniae , and 69 % (22/32) for E. coli , and to carbapenems 64% (7/11) for Acinetobacter spp., 60% (3/5) for Enterobacter spp., 43% (3/7) for E. coli , 30% (7/23) for P. aeruginosa and 29% (9/31) for K. pneumoniae . Four of 11 S. aureus isolates were methicillin‐resistant. A blood culture was done in only 52% (16/31) of sepsis patients, and the results of positive blood cultures were reported after a median of 4 days. Conclusions: This survey identified that a high proportion of common gram‐negative bacteria exhibited reduced susceptibility to first‐choice antibiotics and considerable underuse of bacterial cultures. These findings warrant enhanced infection prevention and control and antimicrobial stewardship.
- 29 May 2026
- Published by Wiley in Tropical Medicine & International Health
- Vol. 31 (9) , 1231-1237
Open AccessAetiology and Antibiotic Susceptibility of Common Bacterial Infections in Hospitalised Patients: A 2019 Multisite Cross‐Sectional Survey in Jakarta, Indonesia
Objectives: To describe the aetiology and antibiotic susceptibility patterns of common bacterial infections in hospitalised patients in Jakarta, Indonesia. Methods: We conducted a hospital‐wide point prevalence survey in six hospitals in 2019, capturing data from routinely ordered bacterial cultures taken before the start of antibiotic treatment. We report relevant bacteria‐antibiotic combinations for Escherichia coli and the ESKAPE group of pathogens. Results: A total of 562 patients (52% women, median age 46 years) were diagnosed with 587 infections, comprising 414 community‐acquired and 173 hospital‐acquired infections, with pneumonia most frequent (258, 44%). From 615 samples collected, 279 (45%) bacterial isolates were identified, of which 213 (76%) gram‐negative, including Klebsiella pneumoniae (68, 24%), Escherichia coli (37, 13%) and Pseudomonas aeruginosa (35, 13%) among others, and 66 (24%) gram‐positive, including Enterococcus faecalis (17, 6%) and Staphylococcus aureus (11, 4%) among others. Proportions of bacteria resistant to third‐generation cephalosporins (3GC) were 75% (47/63) for Klebsiella pneumoniae , and 69 % (22/32) for E. coli , and to carbapenems 64% (7/11) for Acinetobacter spp., 60% (3/5) for Enterobacter spp., 43% (3/7) for E. coli , 30% (7/23) for P. aeruginosa and 29% (9/31) for K. pneumoniae . Four of 11 S. aureus isolates were methicillin‐resistant. A blood culture was done in only 52% (16/31) of sepsis patients, and the results of positive blood cultures were reported after a median of 4 days. Conclusions: This survey identified that a high proportion of common gram‐negative bacteria exhibited reduced susceptibility to first‐choice antibiotics and considerable underuse of bacterial cultures. These findings warrant enhanced infection prevention and control and antimicrobial stewardship.
- Open Access
- 14 May 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (6)
Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010–24): a systematic review and meta-analysis
- 14 May 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (6)
Open AccessAntimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010–24): a systematic review and meta-analysis
- 11 May 2026
- p. 101361
Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010-24): a systematic review and meta-analysis.
Data on the prevalence of antimicrobial resistance (AMR) among the main bacterial pathogens causing community-acquired lower respiratory tract infections (CA-LRTIs) and hospital-acquired lower respiratory tract infections (HA-LRTIs) are scarce. This review estimated LRTI-specific AMR prevalence and time trends globally and for each WHO region. In this systematic review and meta-analysis, we systematically searched Embase, Global Health, and MEDLINE for original peer-reviewed articles, published between Jan 1, 2010, and May 16, 2024, describing microbiologically confirmed LRTI caused by WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) target bacteria, alongside antimicrobial susceptibility testing results. We included studies describing individuals seeking care at a health-care facility with a microbiologically confirmed LRTI, a culture-confirmed GLASS target bacterial pathogen from a lower respiratory tract or expectorated sputum specimen, and antimicrobial susceptibility testing results for one GLASS pathogen-antimicrobial combination or more, for 20 isolates or more. We excluded non-original or non-peer-reviewed articles. We used multilevel random-effect meta-analysis to estimate AMR prevalence for relevant pathogen-antimicrobial combinations. To assess article quality, we adopted the Microbiology Investigation Criteria for Reporting Objectively (MICRO) checklist. This review was registered with PROSPERO (CRD42024549753). From 10 208 reports identified after deduplication, we included 506 reports and extracted data on 336 389 respiratory isolates from 51 countries. For CA-LRTIs, regional variations were observed in the prevalence of penicillin resistance in Streptococcus pneumoniae (32·4% globally [range: 26·5-38·7]; n=6475 isolates); ampicillin resistance in Haemophilus influenzae (51·6% [27·0-73·4]; n=4305); third-generation cephalosporin resistance (38·8% [21·3-84·0]; n=4198) and carbapenem resistance (7·2% [1·2-29·0]; n=3437) in Klebsiella pneumoniae; and meticillin resistance in Staphylococcus aureus (MRSA; 33·2% [11·0-43·2]; n=4698). For HA-LRTIs, regional prevalence of carbapenem resistance varied for Acinetobacter spp (86·0% [78·7-93·4]; n=17 843), Pseudomonas aeruginosa (42·1% [32·3-48·6]; n=22 341), K pneumoniae (37·0% [6·9-52·3]; n=8310), and Escherichia coli (13·2% [0·41-45·2]; n=6229); and for MRSA (55·2% [22·3-79·0]; n=6060). For HA-LRTIs, prevalence of third-generation cephalosporin resistance and carbapenem resistance in E coli was higher in low-income and middle-income countries (73·2% [65·5-80·3] vs 18·3% [5·2-37·0], p<0·001) than in high-income countries (23·2% [8·3-42·8] vs 0·30% [0·0-12·8], p<0·001). Between 2010 and 2021, overall prevalence of penicillin-resistant S pneumoniae declined and that of ampicillin-resistant H influenzae increased globally, both in high-income countries and low-income and middle-income countries, and in adults and children; carbapenem resistance in Gram-negative bacteria increased across multiple regions and globally; and MRSA increased globally. Among the 38 pathogen-antimicrobial combinations assessed, AMR prevalence was higher in HA-LRTI for 18 combinations (47·4%), in CA-LRTI for nine (23·7%), and did not differ for 11 (28·9%). AMR in LRTIs is concerningly high, with pronounced regional and socioeconomic disparities. Systematic literature reviews can provide a complementary data source to national AMR surveillance, to better inform public health interventions. Fleming Fund, US Centers for Disease Control and Prevention, WHO.
- 11 May 2026
- p. 101361
Antimicrobial resistance in bacterial pathogens causing community-acquired and hospital-acquired lower respiratory tract infections (2010-24): a systematic review and meta-analysis.
Data on the prevalence of antimicrobial resistance (AMR) among the main bacterial pathogens causing community-acquired lower respiratory tract infections (CA-LRTIs) and hospital-acquired lower respiratory tract infections (HA-LRTIs) are scarce. This review estimated LRTI-specific AMR prevalence and time trends globally and for each WHO region. In this systematic review and meta-analysis, we systematically searched Embase, Global Health, and MEDLINE for original peer-reviewed articles, published between Jan 1, 2010, and May 16, 2024, describing microbiologically confirmed LRTI caused by WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) target bacteria, alongside antimicrobial susceptibility testing results. We included studies describing individuals seeking care at a health-care facility with a microbiologically confirmed LRTI, a culture-confirmed GLASS target bacterial pathogen from a lower respiratory tract or expectorated sputum specimen, and antimicrobial susceptibility testing results for one GLASS pathogen-antimicrobial combination or more, for 20 isolates or more. We excluded non-original or non-peer-reviewed articles. We used multilevel random-effect meta-analysis to estimate AMR prevalence for relevant pathogen-antimicrobial combinations. To assess article quality, we adopted the Microbiology Investigation Criteria for Reporting Objectively (MICRO) checklist. This review was registered with PROSPERO (CRD42024549753). From 10 208 reports identified after deduplication, we included 506 reports and extracted data on 336 389 respiratory isolates from 51 countries. For CA-LRTIs, regional variations were observed in the prevalence of penicillin resistance in Streptococcus pneumoniae (32·4% globally [range: 26·5-38·7]; n=6475 isolates); ampicillin resistance in Haemophilus influenzae (51·6% [27·0-73·4]; n=4305); third-generation cephalosporin resistance (38·8% [21·3-84·0]; n=4198) and carbapenem resistance (7·2% [1·2-29·0]; n=3437) in Klebsiella pneumoniae; and meticillin resistance in Staphylococcus aureus (MRSA; 33·2% [11·0-43·2]; n=4698). For HA-LRTIs, regional prevalence of carbapenem resistance varied for Acinetobacter spp (86·0% [78·7-93·4]; n=17 843), Pseudomonas aeruginosa (42·1% [32·3-48·6]; n=22 341), K pneumoniae (37·0% [6·9-52·3]; n=8310), and Escherichia coli (13·2% [0·41-45·2]; n=6229); and for MRSA (55·2% [22·3-79·0]; n=6060). For HA-LRTIs, prevalence of third-generation cephalosporin resistance and carbapenem resistance in E coli was higher in low-income and middle-income countries (73·2% [65·5-80·3] vs 18·3% [5·2-37·0], p<0·001) than in high-income countries (23·2% [8·3-42·8] vs 0·30% [0·0-12·8], p<0·001). Between 2010 and 2021, overall prevalence of penicillin-resistant S pneumoniae declined and that of ampicillin-resistant H influenzae increased globally, both in high-income countries and low-income and middle-income countries, and in adults and children; carbapenem resistance in Gram-negative bacteria increased across multiple regions and globally; and MRSA increased globally. Among the 38 pathogen-antimicrobial combinations assessed, AMR prevalence was higher in HA-LRTI for 18 combinations (47·4%), in CA-LRTI for nine (23·7%), and did not differ for 11 (28·9%). AMR in LRTIs is concerningly high, with pronounced regional and socioeconomic disparities. Systematic literature reviews can provide a complementary data source to national AMR surveillance, to better inform public health interventions. Fleming Fund, US Centers for Disease Control and Prevention, WHO.
- Open Access
Impact of COVID-19 pandemic on childhood immunization coverage in Indonesia: lesson learned from a nationwide analysis of the Expanded Programme on Immunization
Background: The COVID-19 pandemic disrupted childhood immunization programmes in many countries worldwide. However, evidence on its impact in low and middle-income countries remains limited. This study examined the impact of the COVID-19 pandemic on childhood immunization coverage across 514 districts in Indonesia and identified district-level associated factors. Methods: We conducted a nationwide longitudinal analysis of the Expanded Programme on Immunization to compare immunization coverage before and after the pandemic. The outcome variable was the annual childhood immunization coverage (proportion of children aged 0-12 months who have received all recommended doses of childhood immunization as per the national immunization schedule). The explanatory variables include COVID-19 burden and vaccination rates, health system and human development indicators. Mixed-effect logistic regression was done to assess association between the explanatory and outcome variables. Results: At the national level, the coverage was 83.2% in pre-pandemic, 75.0% in the first year of pandemic, and 88.6%, in the second. In the first year, 69.3% of districts experienced significant decline, with a lower national coverage ratio of 0.92 (95% confidence interval 0.89–0.94). In the second year, 36.2% districts were still affected. The multivariable analysis showed that a significant decline in coverage during the first pandemic year was associated with high COVID-19 incidence (adjusted odds ratio 2.19, 95%CI 1.01–4.73 for the highest vs. lowest group), low midwife adequacy (5.84, 2.40–14.16 for the lowest vs. the highest group, 2.61, 1.26–5.40 for low-middle vs. the highest group), and a high proportion of health facility-based births (2.98, 1.49–5.98 for middle-high vs. the lowest group). Conclusions: The COVID-19 pandemic negatively and unevenly impacted childhood immunization in Indonesia, with greatest impacts in districts facing a higher COVID-19 burden and weaker health system capacity. These findings underscore the need for targeted efforts to strengthen the local health system for future health crises. Summary box: What is already known on this topic: According to the WHO Pulse Survey, routine immunizations were the most disrupted essential health services during the COVID-19 pandemic, reported by 70% of countries. Southeast Asia experienced the steepest drop in childhood immunization coverage compared to the other regions. Indonesia had the highest number of COVID-19 cases and related mortality in Southeast Asia. However, the magnitude and heterogeneity of the impact of COVID-19 pandemic on childhood immunization coverage across all 514 districts in Indonesia has not been evaluated. What this study adds: This study affirmed that the COVID-19 pandemic greatly impacted childhood immunization coverage, disproportionately impacting district with vulnerable health systems capacity. How this study might affect research, practice, or policy: This study highlights the critical need of addressing health inequity to strengthen health system resilience for future global health crises. In the context of a decentralised health system such as in Indonesia, coordination and prioritisation of available resources and public health intervention will be critical to ensure optimal health outcomes for children living in districts with weak health systems.
Open AccessImpact of COVID-19 pandemic on childhood immunization coverage in Indonesia: lesson learned from a nationwide analysis of the Expanded Programme on Immunization
Background: The COVID-19 pandemic disrupted childhood immunization programmes in many countries worldwide. However, evidence on its impact in low and middle-income countries remains limited. This study examined the impact of the COVID-19 pandemic on childhood immunization coverage across 514 districts in Indonesia and identified district-level associated factors. Methods: We conducted a nationwide longitudinal analysis of the Expanded Programme on Immunization to compare immunization coverage before and after the pandemic. The outcome variable was the annual childhood immunization coverage (proportion of children aged 0-12 months who have received all recommended doses of childhood immunization as per the national immunization schedule). The explanatory variables include COVID-19 burden and vaccination rates, health system and human development indicators. Mixed-effect logistic regression was done to assess association between the explanatory and outcome variables. Results: At the national level, the coverage was 83.2% in pre-pandemic, 75.0% in the first year of pandemic, and 88.6%, in the second. In the first year, 69.3% of districts experienced significant decline, with a lower national coverage ratio of 0.92 (95% confidence interval 0.89–0.94). In the second year, 36.2% districts were still affected. The multivariable analysis showed that a significant decline in coverage during the first pandemic year was associated with high COVID-19 incidence (adjusted odds ratio 2.19, 95%CI 1.01–4.73 for the highest vs. lowest group), low midwife adequacy (5.84, 2.40–14.16 for the lowest vs. the highest group, 2.61, 1.26–5.40 for low-middle vs. the highest group), and a high proportion of health facility-based births (2.98, 1.49–5.98 for middle-high vs. the lowest group). Conclusions: The COVID-19 pandemic negatively and unevenly impacted childhood immunization in Indonesia, with greatest impacts in districts facing a higher COVID-19 burden and weaker health system capacity. These findings underscore the need for targeted efforts to strengthen the local health system for future health crises. Summary box: What is already known on this topic: According to the WHO Pulse Survey, routine immunizations were the most disrupted essential health services during the COVID-19 pandemic, reported by 70% of countries. Southeast Asia experienced the steepest drop in childhood immunization coverage compared to the other regions. Indonesia had the highest number of COVID-19 cases and related mortality in Southeast Asia. However, the magnitude and heterogeneity of the impact of COVID-19 pandemic on childhood immunization coverage across all 514 districts in Indonesia has not been evaluated. What this study adds: This study affirmed that the COVID-19 pandemic greatly impacted childhood immunization coverage, disproportionately impacting district with vulnerable health systems capacity. How this study might affect research, practice, or policy: This study highlights the critical need of addressing health inequity to strengthen health system resilience for future global health crises. In the context of a decentralised health system such as in Indonesia, coordination and prioritisation of available resources and public health intervention will be critical to ensure optimal health outcomes for children living in districts with weak health systems.
- Open Access
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Contextual Determinants of Antimicrobial Stewardship Implementation in Healthcare Facilities: A Four-Country Mixed-Methods Study in South and Southeast Asia
Background: Antimicrobial stewardship (AMS) implementation is highly context-dependent. This mixed-methods study assessed contextual determinants influencing AMS implementation at national, facility, and healthcare-provider levels in four Asian countries.Methods: We used the World Health Organization’s National AMS assessment tool in Indonesia, Nepal, Thailand, and Viet Nam. Facility-level implementation was evaluated using the US Centers for Disease Control and Prevention’s Global Antibiotic Stewardship Evaluation Tool (G-ASET) in 16 hospitals across these countries. Data collection included staff surveys, interviews, and focus group discussions.Findings: All four countries had national AMS policies, and two incorporated financing mechanisms into national action plans. Main areas for further improvement were the development of stewardship guidelines for primary care and community settings; stronger linkages across related sectors and programs; expanded professional training; strengthened regulatory enforcement; systematic performance tracking; and better data use for feedback and decision-making. Among the 16 hospitals, the mean G-ASET score was 241/335 (72%), highest in tracking, monitoring and reporting [56/75 (75%)] and lowest in training and education [17/25 (66%)]. Private and larger hospitals (>500 beds) achieved higher scores. Although all hospitals had initiated AMS activities, implementation was often partial, with gaps in data-informed treatment guidelines, staff training, and resources.Interpretation: National treatment and stewardship guidelines and workforce training are critical for strengthening facility-level AMS implementation. Enhancing inter-program coordination and support for small-size hospitals and primary care settings in Asia will be essential to advance AMS implementation.
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessContextual Determinants of Antimicrobial Stewardship Implementation in Healthcare Facilities: A Four-Country Mixed-Methods Study in South and Southeast Asia
Background: Antimicrobial stewardship (AMS) implementation is highly context-dependent. This mixed-methods study assessed contextual determinants influencing AMS implementation at national, facility, and healthcare-provider levels in four Asian countries.Methods: We used the World Health Organization’s National AMS assessment tool in Indonesia, Nepal, Thailand, and Viet Nam. Facility-level implementation was evaluated using the US Centers for Disease Control and Prevention’s Global Antibiotic Stewardship Evaluation Tool (G-ASET) in 16 hospitals across these countries. Data collection included staff surveys, interviews, and focus group discussions.Findings: All four countries had national AMS policies, and two incorporated financing mechanisms into national action plans. Main areas for further improvement were the development of stewardship guidelines for primary care and community settings; stronger linkages across related sectors and programs; expanded professional training; strengthened regulatory enforcement; systematic performance tracking; and better data use for feedback and decision-making. Among the 16 hospitals, the mean G-ASET score was 241/335 (72%), highest in tracking, monitoring and reporting [56/75 (75%)] and lowest in training and education [17/25 (66%)]. Private and larger hospitals (>500 beds) achieved higher scores. Although all hospitals had initiated AMS activities, implementation was often partial, with gaps in data-informed treatment guidelines, staff training, and resources.Interpretation: National treatment and stewardship guidelines and workforce training are critical for strengthening facility-level AMS implementation. Enhancing inter-program coordination and support for small-size hospitals and primary care settings in Asia will be essential to advance AMS implementation.
- Open Access
- 15 April 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (4) , e70111
A Four‐Item Risk Score to Target Acute HIV Infection Testing Among Men Who Have Sex With Men in Indonesia: Development and Validation in the INTERACT Prospective Cohort
Introduction: Indonesia has an escalated HIV epidemic among key populations, especially men who have sex with men (MSM). Diagnosis and immediate treatment of acute HIV infection (AHI), the earliest phase with the highest transmission risk, is beneficial for individual health and can reduce onward transmission. To inform whom to test for possible AHI using targeted, risk‐stratified HIV‐PCR testing, this study evaluated the performance of the validated, seven‐item Amsterdam AHI risk score among Indonesian MSM, and developed a locally optimized score. Methods: We used the INTERACT prospective cohort of MSM (≥16 years) attending sexual health clinics in Jakarta and Bali (May 2023−February 2025) who were tested with add‐on Xpert HIV‐PCR (Cepheid) if their HIV antibody rapid testing was negative or inconclusive. We used generalized estimating equation models to generate risk scores, combining symptoms, risk factors and socio‐demographics. The optimized risk score was internally validated using bootstrap resampling. We calculated area under the curve (AUC), sensitivity and specificity (ISRCTN41396071). Results: Among 1887 individuals, 20 were diagnosed with AHI, and 1867 tested AHI negative across 3446 test visits. The Amsterdam score yielded an AUC of 0.82 (95% CI 0.75−0.90) with a sensitivity of 85.0% (64.0%−94.8%) and a specificity of 59.2% (57.5−60.8). The optimized risk score included one symptom (fever <2 weeks), one risk factor (condomless receptive anal intercourse <6 months) and two socio‐demographic characteristics (age 16–30 years, not having received higher education), and achieved an AUC of 0.91 (0.87−0.96) with a sensitivity of 100% (83.9−100) and a specificity of 65.3% (63.6%−66.8%). Internal validation yielded an AUC of 0.86 (0.67−0.97). Applying this risk score would classify 35.1% of MSM as eligible for add‐on HIV‐PCR testing, identifying 83.9%–100% of individuals who have AHI. Conclusions: This four‐item risk score of easily collected variables can facilitate efficient AHI detection in high‐yield clinic settings, enhancing opportunities for HIV prevention. In the Indonesian context, younger MSM with lower educational attainment were particularly vulnerable to AHI.
- 15 April 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (4) , e70111
Open AccessA Four‐Item Risk Score to Target Acute HIV Infection Testing Among Men Who Have Sex With Men in Indonesia: Development and Validation in the INTERACT Prospective Cohort
Introduction: Indonesia has an escalated HIV epidemic among key populations, especially men who have sex with men (MSM). Diagnosis and immediate treatment of acute HIV infection (AHI), the earliest phase with the highest transmission risk, is beneficial for individual health and can reduce onward transmission. To inform whom to test for possible AHI using targeted, risk‐stratified HIV‐PCR testing, this study evaluated the performance of the validated, seven‐item Amsterdam AHI risk score among Indonesian MSM, and developed a locally optimized score. Methods: We used the INTERACT prospective cohort of MSM (≥16 years) attending sexual health clinics in Jakarta and Bali (May 2023−February 2025) who were tested with add‐on Xpert HIV‐PCR (Cepheid) if their HIV antibody rapid testing was negative or inconclusive. We used generalized estimating equation models to generate risk scores, combining symptoms, risk factors and socio‐demographics. The optimized risk score was internally validated using bootstrap resampling. We calculated area under the curve (AUC), sensitivity and specificity (ISRCTN41396071). Results: Among 1887 individuals, 20 were diagnosed with AHI, and 1867 tested AHI negative across 3446 test visits. The Amsterdam score yielded an AUC of 0.82 (95% CI 0.75−0.90) with a sensitivity of 85.0% (64.0%−94.8%) and a specificity of 59.2% (57.5−60.8). The optimized risk score included one symptom (fever <2 weeks), one risk factor (condomless receptive anal intercourse <6 months) and two socio‐demographic characteristics (age 16–30 years, not having received higher education), and achieved an AUC of 0.91 (0.87−0.96) with a sensitivity of 100% (83.9−100) and a specificity of 65.3% (63.6%−66.8%). Internal validation yielded an AUC of 0.86 (0.67−0.97). Applying this risk score would classify 35.1% of MSM as eligible for add‐on HIV‐PCR testing, identifying 83.9%–100% of individuals who have AHI. Conclusions: This four‐item risk score of easily collected variables can facilitate efficient AHI detection in high‐yield clinic settings, enhancing opportunities for HIV prevention. In the Indonesian context, younger MSM with lower educational attainment were particularly vulnerable to AHI.
- Open Access
- 18 March 2026
- Published by Elsevier in SSRN Electronic Journal
Immunogenicity of IndoVac, a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, as a fifth-dose booster, compared with prior mRNA vaccine boosters: a longitudinal cohort study in Indonesian healthcare workers
Objectives Immunogenicity of IndoVac (BioFarma), a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, has not been well-studied. We evaluated fifth-dose IndoVac, following third- and fourth-dose mRNA vaccination, among Indonesian healthcare workers (HCWs). Methods Between August 2023 and January 2025, we measured anti-S-RBD IgG titres, neutralising antibody (nAb) titres against six Omicron-subvariants, and IFN-γ T-cell responses, before and 28 days after vaccine dose 3-5 in 30 HCWs. Results Anti-S-RBD IgG and nAb titres increased after third-dose mRNA vaccine (34.7-fold and 28.4–61.9-fold, respectively) and increased further after fourth-dose mRNA vaccine (4.2-fold and 4.8–6.8-fold, respectively), whereas fifth-dose IndoVac did not further improve antibody titres (1.3-fold and 1.9–4.1-fold decline, respectively). nAb titres against XBB-subvariants were consistently lower than against ancestral-strain. IFN-γ T-cell responses were detectable in most individuals after respective third, fourth, and fifth doses, both against ancestral-strain (91.7%, 100%, and 90.0%) and Omicron BA 2.86 (66.7%, 100%, and 100%). T-cell responses increased 3.6-fold after third-dose and remained stable thereafter. Conclusions Compared to immunogenic mRNA booster, IndoVac did not boost humoral or cellular immune responses against ancestral and Omicron-subvariants. These findings support efforts to advance domestic vaccine manufacturing capacity in LMICs, to ensure vaccine formulations can effectively target emerging SARS-CoV-2 variants.
- 18 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImmunogenicity of IndoVac, a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, as a fifth-dose booster, compared with prior mRNA vaccine boosters: a longitudinal cohort study in Indonesian healthcare workers
Objectives Immunogenicity of IndoVac (BioFarma), a domestically manufactured SARS-CoV-2 protein subunit ancestral-strain vaccine, has not been well-studied. We evaluated fifth-dose IndoVac, following third- and fourth-dose mRNA vaccination, among Indonesian healthcare workers (HCWs). Methods Between August 2023 and January 2025, we measured anti-S-RBD IgG titres, neutralising antibody (nAb) titres against six Omicron-subvariants, and IFN-γ T-cell responses, before and 28 days after vaccine dose 3-5 in 30 HCWs. Results Anti-S-RBD IgG and nAb titres increased after third-dose mRNA vaccine (34.7-fold and 28.4–61.9-fold, respectively) and increased further after fourth-dose mRNA vaccine (4.2-fold and 4.8–6.8-fold, respectively), whereas fifth-dose IndoVac did not further improve antibody titres (1.3-fold and 1.9–4.1-fold decline, respectively). nAb titres against XBB-subvariants were consistently lower than against ancestral-strain. IFN-γ T-cell responses were detectable in most individuals after respective third, fourth, and fifth doses, both against ancestral-strain (91.7%, 100%, and 90.0%) and Omicron BA 2.86 (66.7%, 100%, and 100%). T-cell responses increased 3.6-fold after third-dose and remained stable thereafter. Conclusions Compared to immunogenic mRNA booster, IndoVac did not boost humoral or cellular immune responses against ancestral and Omicron-subvariants. These findings support efforts to advance domestic vaccine manufacturing capacity in LMICs, to ensure vaccine formulations can effectively target emerging SARS-CoV-2 variants.
- Open Access
- 27 January 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (2) , 101238
Antimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010–24): a systematic review and meta-analysis
- 27 January 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (2) , 101238
Open AccessAntimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010–24): a systematic review and meta-analysis